Last reviewed · How we verify

Valsartan/aliskiren — Competitive Intelligence Brief

Valsartan/aliskiren (Valsartan/aliskiren) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor blocker + direct renin inhibitor combination. Area: Cardiovascular.

marketed Angiotensin II receptor blocker + direct renin inhibitor combination AT1 receptor (valsartan); renin (aliskiren) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Valsartan/aliskiren (Valsartan/aliskiren) — Novartis. This combination blocks two pathways in the renin-angiotensin-aldosterone system: valsartan blocks angiotensin II receptors while aliskiren inhibits renin, reducing blood pressure through dual inhibition.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Valsartan/aliskiren TARGET Valsartan/aliskiren Novartis marketed Angiotensin II receptor blocker + direct renin inhibitor combination AT1 receptor (valsartan); renin (aliskiren)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor blocker + direct renin inhibitor combination class)

  1. Novartis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Valsartan/aliskiren — Competitive Intelligence Brief. https://druglandscape.com/ci/valsartan-aliskiren. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: